[go: up one dir, main page]

MX2010003281A - Sales de un antagonista de cgrp, metodos para su produccion y su uso como medicamento. - Google Patents

Sales de un antagonista de cgrp, metodos para su produccion y su uso como medicamento.

Info

Publication number
MX2010003281A
MX2010003281A MX2010003281A MX2010003281A MX2010003281A MX 2010003281 A MX2010003281 A MX 2010003281A MX 2010003281 A MX2010003281 A MX 2010003281A MX 2010003281 A MX2010003281 A MX 2010003281A MX 2010003281 A MX2010003281 A MX 2010003281A
Authority
MX
Mexico
Prior art keywords
acid
novel compounds
silcylic
hydrates
group
Prior art date
Application number
MX2010003281A
Other languages
English (en)
Inventor
Sonja Sproll
Ulrike Werthmann
Kathrin Pachur
Uwe Joerg Ries
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003281(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2010003281A publication Critical patent/MX2010003281A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invenci?n se refiere a las nuevas sales AB de la base A (ver f?rmula A) con un ?cido de fisiol?gicamente tolerable B, que est? seleccionado del grupo compuesto por ?cido clorh?drico, ?cido bromh?drico, ?cido sulf?rico, ?cido fum?rico y ?cido salic?lico, as? como los polimorfos, los correspondientes solvatos e hidratos.
MX2010003281A 2007-09-28 2008-09-25 Sales de un antagonista de cgrp, metodos para su produccion y su uso como medicamento. MX2010003281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007046888 2007-09-28
PCT/EP2008/062847 WO2009043797A2 (de) 2007-09-28 2008-09-25 Salze eines cgrp antagonisten, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
MX2010003281A true MX2010003281A (es) 2010-04-09

Family

ID=40032737

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003281A MX2010003281A (es) 2007-09-28 2008-09-25 Sales de un antagonista de cgrp, metodos para su produccion y su uso como medicamento.

Country Status (16)

Country Link
US (1) US8551987B2 (es)
EP (1) EP2205587A2 (es)
JP (1) JP2010540494A (es)
KR (1) KR20100058598A (es)
CN (1) CN101809015A (es)
AR (1) AR068570A1 (es)
AU (1) AU2008306968A1 (es)
BR (1) BRPI0817585A2 (es)
CA (1) CA2700928A1 (es)
CL (1) CL2008002897A1 (es)
IL (1) IL204705A0 (es)
MX (1) MX2010003281A (es)
PE (1) PE20091206A1 (es)
TW (1) TW200922599A (es)
UY (1) UY31365A1 (es)
WO (1) WO2009043797A2 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005038831A1 (de) 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
WO2009043797A3 (de) 2009-07-02
UY31365A1 (es) 2009-04-30
JP2010540494A (ja) 2010-12-24
EP2205587A2 (de) 2010-07-14
TW200922599A (en) 2009-06-01
CA2700928A1 (en) 2009-04-09
AR068570A1 (es) 2009-11-18
IL204705A0 (en) 2010-11-30
US20120058994A1 (en) 2012-03-08
BRPI0817585A2 (pt) 2015-03-31
WO2009043797A2 (de) 2009-04-09
CN101809015A (zh) 2010-08-18
CL2008002897A1 (es) 2010-03-05
AU2008306968A1 (en) 2009-04-09
KR20100058598A (ko) 2010-06-03
US8551987B2 (en) 2013-10-08
PE20091206A1 (es) 2009-09-14

Similar Documents

Publication Publication Date Title
ZA201105992B (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
MX2009008275A (es) Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c.
SI2344465T1 (sl) Kristaliniäśne oblike (r)-5-(3-kloro-4-(2,3-dihidroksi-propoksi)- benz(z)iliden)-2-(z)-propilimino)-3-o-tolil-tiazolidin-4-ona
GEP20125491B (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
UA94833C2 (en) Substituted bicyclolactams
GEP20125712B (en) Method for preparation of piperazine compounds and hydrochloride salts thereof
NO20072977L (no) Aryloksyetylaminderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
IL183237A0 (en) Polymorphs of memantine hydrochloride
TNSN08191A1 (en) Kinase inhibitors
MX351611B (es) Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
UA101091C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
MX2012001890A (es) Sales de lenalidomida.
MX2010003213A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
GEP20146019B (en) Novel method of synthesizing ivabradine and pharmaceutically acceptable acid-additive salts thereof
WO2009039362A3 (en) Chiral synthesis of diazepinoquinolines
TW200745049A (en) New crystalline forms
IL196200A0 (en) Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin-10,10-dioxide
MX2010003281A (es) Sales de un antagonista de cgrp, metodos para su produccion y su uso como medicamento.
SG165254A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
EA022785B8 (ru) Стереоселективный синтез производных пиперидина
MY146777A (en) Process for preparing substituted 1, 4-quinone methides
UA98698C2 (en) Phenylsulfanylphenyl-piperidines and process for the preparation thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal